DIAG-723
/ Diagonal Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
July 03, 2026
DIAMOND: DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
(clinicaltrials.gov)
- P1/2 | N=93 | Recruiting | Sponsor: Diagonal Therapeutics, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Cardiovascular • Hematological Disorders • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
April 13, 2026
Living with PAH and HHT - Investigating a novel therapy in the DIAMOND Trial
(PHA 2026)
- "Attendees will hear about DIAG723, a novel bispecific antibody therapy that could treat both diseases simultaneously, and the DIAMOND trial, a first-in-human clinical trial of DIAG723...The DIAMOND trial represents the first opportunity to evaluate this approach in patients living with both conditions. Attend this session to learn more about the science, the trial, and how patients can get involved."
First-in-human • Cardiovascular • Genetic Disorders • Hematological Disorders • Pulmonary Arterial Hypertension • Respiratory Diseases • ALK1
June 04, 2026
DIAMOND: DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
(clinicaltrials.gov)
- P1/2 | N=93 | Not yet recruiting | Sponsor: Diagonal Therapeutics, Inc.
First-in-human • New P1/2 trial • Cardiovascular • Hematological Disorders • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
June 18, 2025
Diagonal's First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
(The Manila Times)
- "Diagonal Therapeutics...announced that both the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to DIAG723, a novel, bispecific antibody, for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the European Medicines Agency (EMA) provided a positive opinion for ODD, confirming that DIAG723 meets the criteria for designation as an orphan drug in the European Union."
Orphan drug • Genetic Disorders
1 to 4
Of
4
Go to page
1